Standout Papers

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>... 2022 2026 2023 2024126
  1. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial (2022)
    Eric F. Morand, Marilyn C. Pike et al. Arthritis & Rheumatology

Citation Impact

31 standout
Sub-graph 1 of 12

Citing Papers

An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
NF-κB in biology and targeted therapy: new insights and translational implications
2024 Standout
5 intermediate papers

Works of Nikolay Delev being referenced

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
2022 Standout
Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study
2022
and 1 more

Author Peers

Author Rheumatology Immunology Oncology Hematology Last Decade Papers Cites
Nikolay Delev 275 227 67 98 24 381
Mahboubeh Tasviri 2 26 486
Liang Dong 5 51 30 4 18 316
Michael J. Colle 1 26 315
Marc J. C. Scanio 2 2 13 630
Mel Campbell 4 10

All Works

Loading papers...

Rankless by CCL
2026